Indolinones as promising scaffold as kinase inhibitors: A review

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 98-119

  Prakash, C R ^a   Raja, S ^b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b GITAM UNIVERSITY   (India)

Author keywords

Anticancer; Growth factor; Indole; Inhibitor; Isatin; Kinase

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 3 [1 (3H IMIDAZOL 4 YL)METHYLIDENE] 5 METHOXY 1,3 DIHYDRO INDOL 2 ONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 [(5 CHLORO 2 OXO 1,2 DIHYDRO 3H INDOL 3YLIDENE)METHYL] N [2 (DIETHYL AMINO)ETHYL] 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 5 [6 [3 (4 METHOXYPHENYL)UREIDO] 2 OXO 1,2 DIHYDROINDOL 3 YLIDENE METHYL] 4 METHYL 1H PYRROLE 3 CARBOXYLIC ACID; 5,7 DIMETHOXY PHENYL INDOLIN 2 ONE; ANTINEOPLASTIC AGENT; B 5; BIBF 1000; ETHYL 3,5 DIMETHYL 4 [(INDOLIN 2 ONE 3 YLIDENE)METHYL] 1H PYRROLE 2 CARBOXYLATE; HESPERADIN; INDIRUBIN; INDOLINONE DERIVATIVE; LAPATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N DEETHYLSUNITINIB; NINTEDANIB; NP 506; ORANTINIB; PHOSPHOTRANSFERASE INHIBITOR; SEMAXANIB; SU 10944; SU 4984; SU 5614; SU 9516; SUNITINIB; TOCERANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARGATE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER INHIBITION; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; ESOPHAGUS CARCINOMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYDROGEN BOND; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; MASTOCYTOMA; MELANOMA; METASTASIS; MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; REVIEW; SARCOMA; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856480124     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712798995039     Document Type: Review

References (115)

1. Smith, B.D.; Smith, G.L.; Hurria, A.; Hortobagyi, G.N.; Buchholz, T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol., 2009, 27, 2758-2765.
2. Cohen, P. The role of reversible protein phosphorylation in health and disease. Eur. J. Biochem., 2001, 268, 5001-5010.
3. Li, J.L.; Harris, A.L. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front. Biosci., 2009, 14, 3094-3110.
4. Medina, V.; Calvo, M.B.; Diaz-Prado, S. Hedgehog signalling as a target in cancer stem cells. Clin. Transl. Oncol., 2009, 11, 199-207.
5. Wong, K.K. Recent developments in anticancer agents targeting the RAS/RAF/MEK/ ERK pathway. Recent. Pat. Anticancer. Drug. Discov., 2009, 4(1), 28-35.
6. Lai, S.L.; Chien, A.J.; Moon, R.T. Wnt/Fz signaling and the cytoskeleton: Potential roles in tumorigenesis. Cell. Res., 2009, 19(5), 532-545.
7. McDonald, S.L.; Silver, A. The opposing roles of Wnt-5a in cancer. Br. J. cancer., 2009, 101, 209-214.
8. Guo, X.; Wang, X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell. Res., 2009, 19, 71-88.
9. Tian, M.; Schiemann, W.P. The TGF-β paradox in human cancer: an update. Future. Oncol., 2009, 5(2), 259-271.
10. Vogt, P.K.; Gymnopoulos, M.; Hart, J.R. P13-kinase and cancer: changing accents. Curr. Opin. Genet. Dev., 2009, 19(1), 12-17.
11. Brachmann, S.; Fritsch, C.; Maira, S.M.; Echeverria, C.G. P13K and mTOR inhibitors- a new generation of targeted anticancer agents. Curr. Opin. Cell. Biol., 2009, 21(2), 194-198.
12. Gorin, M.A.; Pan, Q. Protein kinase C epsilon: an oncogene and emerging tumor bio marker. Mol. Cancer., 2009, 8, 1-8.
13. Reyland, M.E. Protein kinase C isoforms: multi-functional regulators of cell life and death. Front. Biosci., 2009, 14, 2386-2399.
14. Hartmann, J.T.; Haap, M.; Kopp, H.G.; Lipp, H.P. Tyrosine Kinase Inhibitors-A Review on Pharmacology, Metabolism and Side Effects. Curr. Drug. Metabolism., 2009, 10, 470-481.
15. Kiakos, K.; Sato, A.; Asao, T.; McHugh, P.J.; Lee, M.; Hartley, J.A. DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral secoamino-cyclopropylbenz indolone analogue of duocarmycin ASI-145. Mol. Cancer. Ther., 2007, 6, 2708-2718.
16. Krug, M.; Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini. Rev. Med. Chem., 2008, 8, 1312-1327.
17. Chow, L.Q.; Eckhardt, S.G. Sunitinib: From rational design to clinical efficacy. J. Clin. Oncol., 2007, 25, 884-896.
18. Sandrine, F.; George, D.; William, S.; Eric, R. Molecular basis for Sunitinib efficacy and future clinical development. Nat. Rev. Drug. Discovery., 2007, 6, 734-745.
19. Cheryl, A.L.; Phyllis, B.M.; Stacey, L.W.F.; Joseph, F.B.; Anthony, W.R.; Mona P.R.; Carolyn, J.H.; Kathy, L.M.; Mary, K.K.; John, G.H.; Philip, J.B.; Guillermo, C.C.; Guy, N.M.; Gina, M.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer. Res., 2009, 15, 3856-3865.
20. Donnell, A.O.; Padhani, A.; Hayes, C.; Kakkar, A.J.; Leach, M.; Trigo, J.M.; Scurr, M.; Raynaud, F.; Phillips, S.; Aherne, W.; Hardcastle, A.; Workman, P.; Hannah, A.; Judson, I. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. British. J. Cancer., 2005, 93, 876-883.
21. Matthew, G.F.; Andrew, Z.; Richard, W.; Ennapadam, V.; Eric, L.; Lucy, H.; Timothy, A.; William, G.; Martin, F.; David, G.P. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New. Drugs., 2007, 25, 165-172.
22. http://www.ncbi.nlm.nih.gov/pubmed/15965852.
23. Karsten, S.; Florian, F.; Robert, V.; Wolfgang H. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Experi. Hematology., 2002, 30, 767-773.
24. Cristiana, S.; Lucia, V.; Giacomo, G.; Jose, T.; Irene, M.; Anna, L.; Alberta, B.; Nicoletta, I.; Silvia, M.; Luca, G. Phase I clinical and pharmacological evaluation of the multi tyrosine kinase inhibitor SU006668 by chronic oral Dosing. Eur. J. Cancer., 2006, 42, 171-178.
25. Laird, A.D.; Vajkoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schles singer, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; Fong, T.A.; Strawn, L.M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K.P.; McMahon, G.; Cherrington, J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumor. Cancer. Res., 2000, 60, 4152-4160.
26. Fiedler, W.; Giaccone, G.; Lasch, P.; Horst, I.V.; Brega, N.; Courtney, R.; Abbattista, A.; Shalinsky, D.R.; Bokemeyer, C.; Boven, E. Phase I trial of SU14813 in patients with advanced solid Malignancies. Ann. Oncology., 2011, 22, 195-201.
27. Georgios, G.; Man, Y.L.; Hirner, H.; Bischof, J.; Klaus, K.; Kalimullah, K.; Sharmeen, S.; Lavina, A.; Justin, S.; Knippschild, U. Kinases as targets in the treatment of solid tumors. Cellular. Signalling., 2010, 22, 984-1002.
28. Shem, P.; Laird, A.D.; Mendel, D.B. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer. Ther., 2006, 5, 1774-1782.
29. Xueyan, W.; Phuong, L.; Congxin, L. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/ SF-induced tumor cell growth and invasion. Mol. Cancer. Ther., 2003, 2, 1085-1092.
30. Brett, E.H.; Carlo, L.B.; Dongwoo, K. A population pharmacokinetic meta-analysis of Sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer. Res., 2009, 15, 2497-2506.
31. Grand, E.K.; Chase, A.J.; Heath, C.; Rahemtulla, A.; Cross, N.C.P. Targeting FGFR3 in multiple myeloma: inhibition of t (4;14)- positive cells by SU5402 and PD173074. Leukemia., 2004, 18, 962-966.
32. Neela, P.; Li, S.; Deborah, M.; Hui, C.; Kathleen, M.L.; Phuong, Le.; Katherine, G.M.; Xueyan, W.; Audie, R.; Danny, T.; Laird, A.D.; Xiaoming, Yu.; Qingling, Z.; Cho, T.; Gerald, M.M.; Anthony, H. A selective and oral small molecule inhibitor of VEGFR-2 and VEGFR-1 inhibits neovascularization and vascular permeability. The. J. Pharmacol. Experi. Therapeut., 2003, 306, 838-845.
33. Robert, R.J. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophy. Res. Comm., 2007, 356, 323-328.
34. Nathalie, D.; Carl, S.; Sonia, N.; Serge, C. Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656. Blood. Cells. Molecules. And. Diseases., 2007, 39, 130-134.
35. Deborah, J.M.; Cornelia, R.B.; David, C.B.; Ping, U.; Terence, H.J.J.; Sung, H.K.; Audie, G.R. SU9516: biochemical analysis of CDK inhibition and crystal structure in complex with CDK2. Biochem. Biophy. Res. Comm., 2003, 310, 1026-1031.
36. Lane, ME.; Yu, B.; Rice, A.; Lipson, K.E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R.G.; Wadler, S. A novel CDK2- selective inhibitor SU9516 induces apoptosis in colon carcinoma cells. Cancer. Res., 2001, 61, 6170-6177.
37. Yongsheng, M.; Eric, C.; Xiaomei, W.; Chang, S.; Gerald, M.M.; Longley, B.J. Indolinone derivative inhibit constitutively activated KIT mutants and kill neoplastic mast cells. The. J. Invest. Dermatology., 2000, 114, 392-394.
38. Frank, H.; Roth, G.J.; Martin, K.; et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer. Res., 2008, 68, 4774-4782.
39. Richard, D.C.; Archie, T.; Schwartz, G.K. Aurora Kinases: New Targets for Cancer Therapy. Clin. Cancer. Res., 2006, 12, 6869-6875.
40. Crosswell, H.E.; Dasgupta, A.; Alvarado, C.S.; Watt, T.; Christensen, J.G.; Pradip, D.; Durden, D.L.; Findley, H.W. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC. Cancer., 2009, 9, 411.
41. Watson, G.A.; Zhang, X.; Stang, M.T.; Levy, R.M.; Queiroz P.E.; Gooding, W.E.; Christensen, J.G.; Hughes, S.J. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia., 2006, 8, 949-955.
42. Christensen, J.G.; Schreck, R.; Burrows, J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K.E.; Ramphal, J.; Do, S.; Cui, J.J.; Cherrington, J.M.; Mendel, D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer. Res., 2003, 63, 7345-7355.
43. Xishan, X.; Yingwei, Z.; Xiang, G.; Zheyi, D.; Lin, L.; Chengcheng, J.; Lili, F.; Xiaomin, L.; Hong, L.; Changlin, M. B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest. Invest. New. Drugs., 2010, 28, 26-34.
44. Carmeliet, P.; Jain, H.K. Angiogenesis in cancer and other diseases. Nature., 2000, 407, 249-257.
45. Ferrara, N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine. Netw., 2009, 20, 158-163.
46. Tang, P.C.; Dong, S.Y.; Feng, J.; Hong, F.J.; Yang, J.L.; Xiao, L.; Peng, J.H.; Li, Y.L.; Zhang, L.; Hu, B.; Zhou, Y.; Qiong, L.F.; Bei, F.B.; Lou, L.G.; Gong, A.S.; She, G.H.; Sun, W.H.; Mong, X.T. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. J. Med. Chem., 2010, 53, 8140-8149.
47. Blanche, E.A.; Lesley, M.; Marie, A.C.; Jacqueline, L.W.; Christopher, J.M. Synthesis of potential prodrug systems for reductive activation. Prodrugs for anti-angiogenic isoflavones and VEGF receptor tyrosine kinase inhibitory oxindoles. Tetrahedron., 2009, 65, 4894-4903.
48. Liao, A.T.; Chien, M.B.; Shenoy, N.; Mendel, D.B.; McMahon, G.; Cherrington, J.M.; London, C.A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood., 2002, 100(2), 585-593.
49. Khanwelkar, R.R.; Chen, G.S.; Wang, H.C.; Yu, C.W.; Huang, C.H.; Lee, O.; Chen, C.H et al. Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. Bioorg. Med. Chem., 2010, 18, 4674-4686.
50. Naparat, K.; Chantana, B.; Kingkan, S.; Maleeruk, U.; Satoshi, T.; Hiroaki, S.; Ikuo, S.; Isabelle, A.; Grierson, D.S.; Vajragupta, O. 5- Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorg. Med. Chem. Lett., 2009, 19, 745-750.
51. Sun, L.; Tran, N.; Liang, C.X.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L.K.; McMahon, G.; Tang, C. J. Med. Chem., 1999, 42, 5120-5130.
52. Kulimova, E.; Oelmann, E.; Bisping, G.; Kienast, J.; Mesters, R.M.; Schwable, J.; Hilberg, F.; Roth, G.J.; Munzert, G.; Stefanic, M.; Steffen, B.; Brandts, C.; Muller-Tidow, C.; Kolkmeyer, A.; Buchner, T.; Serve, H.; Berdel, W.E. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, plateletderived growth factor, and vascular endothelial growth factor receptors. Mol. Cancer. Ther., 2006, 5(12), 3105-3112.
53. Roth, G.J.; Armin, H.; Florian, C.; Sandra, H.; Jorg, K.; Thorsten, L.; Ralf, L.; Ulrike, TG.; Rainer, W.; Frank, H. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem., 2009, 52, 4466-4480.
54. Von, P.; Kaiser, J.; Eschbach, C.; Stefanic, M.; Love, J.; Gatzemeier, U.; Reck, M. A double-blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2007, 25, 7635.
55. Naparat, K.; Chantana, B.; Satoshi, T.; Hiroaki, S.; Cikuo, S.; Griersond, D.S.; Vajragupta, O. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2007, 17, 4812-4818.
56. Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol., 2005, 23, 2445-2459.
57. Moy, B.; Kirkpatrick, P.; Kar, S.; Goss, P. Lapatinib. Nat. Rev. Drug. Discov., 2007, 6(6), 431-432.
58. Sun, L.; Ngoc, T.; Flora, T.; Harald, A.; Peter, H.; Gerald, M.; Cho, T. Synthesis and biological evaluations of 3-substituted indolin-2- ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem., 1998, 41, 2588-2603.
59. Klebl, B.M.; Choidas, A. CDK9/cyclin T1: a host cell target for antiretroviral therapy. Fut. Virol., 2006, 1, 317-330.
60. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24, 1770-1783.
61. Xiaoyuan, L.; Ping, H.; Jingrong, J.C.; Jennifer, Z.; Cho, T. Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclindependent kinase 2 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 1939-1942.
62. Bramson, H.N.; John, C.; Davis, S.T.; Dickerson, S.H.; Mark, E.; Stephen, V.F.; Robert, T.G.; Harris, P.A.; Anne, H.; Holmes, W.D.; Hunter, R.N.; Lackey, K.E.; Brett, L.; Luzzio, M.J et al. Oxindolebased inhibitors of cyclin-dependent kinase 2 (cdk2): design, synthesis, enzymatic activities, and x-ray crystallographic analysis. J. Med. Chem., 2001, 44(25), 4339-4358.
63. Woodgett, J.R. Molecular cloning and expression of glycogen synthase kinase-3/factorA. EMBO. J., 1990, 9(8), 2431-2438.
64. Doble, B.W.; Woodgett, J.R. GSK-3: tricks of the trade for a multitasking kinase. J. Cell. Sci. 2003, 116, 1175-1186.
65. Jope, R.S.; Yuskaitis, C.J.; Beurel, E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neuro. Chem. Res., 2007, 32, 577-595.
66. Frame, S.; Cohen, P. GSK-3 takes center stage more than 20 years after its discovery. Biochem. J., 2001, 359, 1-16.
67. Finkelman, H.E. Glycogen synthase kinase-3: an emerging therapeutic target. Trends. Mol. Med., 2002, 8, 126-132.
68. Abadi, A.H.; Abou-Seri, S.M.; Abdel-Rahman, D.E.; Christian, K.; Olivier, L.; Laurent, M. Synthesis of 3-substituted-2-xoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. Eur. J. Med. Chem., 2006, 41, 296-305.
69. Potterat, O.; Hamburger, M. Progress in drug research, natural compounds as drugs; Berlin: Birkhauser Verlag A.G: Switzerland, 2008; pp. 62-64.
70. Hoessel, R.; Leclerc, S.; Endicott, J.A.; Nobel, M.E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol., 1999, 1(1), 60-67.
71. Jautelat, R.; Brumby, T.; Schafer, M.; Briem, H.; Eisenbrand, G.; Schwahn, S.; Kruger, M.; Lucking, U.; Prien, O.; Siemeister, G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chem. Biochem., 2005, 6(3), 531-540.
72. Marko, D.; Schatzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of cyclin-dependent kinase 1(CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer., 2001, 84(2), 283-289.
73. Meijer, L.; Shearer, J.; Bettayeb, K.; Ferandin, Y. Diversity of the intracellular mechanisms underlying the antitumor properties of indirubins. Int. Congres. Ser., 2007, 1304, 60-74.
74. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase- 3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most cycline-dependent kinase inhibitors? J. Biol. Chem., 2001, 276(1), 251-260.
75. Eisenbrand, G.; Hippe, F.; Jakobs, S.; Muehlbeyer, S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer. Res. Clin. Oncol., 2004, 130(11), 627-635.
76. Sethi, G.; Ahn, K.S.; Sandur, S.K.; Lin, X.; Chaturvedi, M.M.; Aggarwal, B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J. Biol. Chem., 2006, 281(33), 23425-23435.
77. Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H.; Miller, C.A.; Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem., 2001, 276(34), 31475-31478.
78. Spink, B.C.; Hussain, M.M.; Katz, B.H.; Eisele, L.; Spink, D.C. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem. Pharmacol., 2003, 66(12), 2313-2321.
79. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A.L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S.M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclindependent kinases. J. Med. Chem., 2004, 47(4), 935-946.
80. Myoung, J.M.; Sang, K.L.; Lee, J.W.; Song, W.K.; Kim, S.K.; Kim, J.I.; Chunghee, C.; Choia, S.J.; Yong-Chul, K. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem., 2006, 14, 237-246.
81. Beauchard, A.; Laborie, H.; Rouillard, H.; Olivier, L.; Yoan, F.; Guevel, R.L.; Guillouzo, C.G.; Meijer, L.; Thierry, B.; Valerie, T. Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorg. Med. Chem., 2009, 17, 6257-6263.
82. Beauchard, A.; Yoan, F.; Stephane, F.; Olivier, L.; Melina, B.; Laurent, M.; Valerie, T.; Thierry, B. Synthesis of novel 5- substituted indirubins as protein kinases inhibitors. Bioorg. Med. Chem., 2006, 14, 6434-6443.
83. Panagiotis, P.; Prokopios, M.; Alexios-Leandros, S.; Vassilios, M. Emmanuel, M.; Aldo, T.; Andrea, M.; et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
84. Sophie, L.; Matthieu, G.; Ralph, H.; Doris, M.; James, A.B.; Snyder, G.L.; Paul, G.; Jacek, B.; Yong-Zhong, W.; Eva-Maria, M.; Gerhard, E.; Laurent, M. Indirubins inhibit glycogen synthase kinase-3b and cdk5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. The. J. Biol. Chem., 2001, 276(1), 251-260.
85. Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/Akt pathways. Oncogene., 2005, 24, 7443-7454.
86. Anderson, S.L.; Stokoe, D.; Erdjument-Bromage, H.; Painter, G.F.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; McCormick, F.; Tempst, P.; Coadwell, J.; Hawkins, P.T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science., 1998, 279, 710-714.
87. Mora, A.; Komander, D.; Van Aalten, D.M.F.; Alessi, D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell. Dev. Biol., 2004, 15, 161-170.
88. Islam, I.; Bryant, J.; Chou, Y.L.; Kochanny, M.J.; Lee, W.; Phillips, G.B.; Yu, H.; Adler, M.; Whitlow, M.; Ho, E.; Lentz, D.; Polokoff, M.A.; Subramanyam, B.; Wu, J.M.; Zhu, D.; Feldman, R.I.; Arnaiz, D.O. Indolinone based phosphoinositide-dependent kinase-1(PDK1) inhibitors. Part 1: Design, synthesis and biological activity. Bioorg. Med. Chem. Lett., 2007, 17, 3814-3818.
89. Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M.J.; Phillips, G.B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M.A.; Wu, J.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R.I.; Arnaiz, D.O. Indolinone based phosphoinositide-dependent kinase-1(PDK1) inhibitors. Part 2: Optimization of BX-517. Bioorg. Med. Chem. Lett., 2007, 17, 3819-3825.
90. Kim, D.W.; Jo, Y.S.; Jung, H.S et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab., 2006, 91, 4070-4076.
91. Mologni, L.; Rostagno, R.; Brussolo, S.; Knowles, P.P.; Kjaer, S.; Murray-Rust, J.; Rosso, E.; Zambon, A.; Scapozza, L.; McDonald, N.Q.; Lucchini, V.; Gambacorti-Passerini, C. Synthesis, structure- activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg. Med. Chem., 2010, 18, 1482-1496.
92. Rizzi, E.; Cassinelli, G.; Dallavalle, S.; Lanzi, C.; Cincinelli, R.; Nannei, R.; Cuccuru, G.; Zunino, F. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2- ones. Bioorg. Med. Chem. Lett., 2007, 17, 3962-3968.
93. Borsello, T.; Forloni, G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharma. Des., 2007, 13, 1875-1886.
94. Gupta, S.; Barrett, T.; Whitmarsh, A.J.; CAvanagh, J.; Sluss, H.K.; Derijard, B.; Davis, R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO. J., 1996, 15, 2760-2770.
95. Lin, A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bio. Essays., 2003, 25(1), 17-24.
96. Cao, J.; Gao, H.; Bemis, G.; Salituro, F.; Ledeboer, M.; Harrington, E.; Wilke, S.; Taslimi, P.; Pazhanisamy, S.; Xie, X.; Jacobs, M.; Green, J. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2891-2895.
97. Ducat, D.; Zheng, Y. Aurora kinases in spindle assembly and chromosome segregation. Exp. Cell. Res., 2004, 301, 60-67.
98. Giet, R.; Petretti, C.; Pringent, C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends. Cell. Biol., 2005, 15(5), 241-50.
99. Wang, X.; Zhou, Y.X.; Qiao, W.; Tominaga, Y.; Ouchi, M.; Ouchi, T.; Deng, C.X. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene., 2006, 25, 7148-7158.
100. Chiang, C.; Lin, Y.H.; Lin, S.F.; Lai, C.L.; Liu, C.; Wei, W.Y.; Yang, S.C.; Wang, R.W.; Teng, L.W.; Chuang, S.H.; Chang, J.M.; Yuan, T.T.; Lee, Y.S.; Chen, P.; Chi, W.K.; Yang, J.Y.; Huang, H.J.; Liao, C.B.; Huang, J.J. Discovery of pyrrole-indoline-2-ones as aurora kinase inhibitors with a different inhibition profile. J. Med. Chem., 2010, 53, 5929-5941.
101. Obeidi, F.A.; Wu, J.J.; Lam, K.S. Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers., 1998, 47, 197-223.
102. Guan, H.; Laird, A.D.; Blake, R.A.; Tanga, C.; Liang, C. Design and synthesis of aminopropyl tetrahydroindole-based indolin-2- ones as selective and potent inhibitors of Src and Yes tyrosine kinase. Bioorg. Med. Chem. Lett., 2004, 14, 187-190.
103. Olgen, S.; Gotz, C.; Jose, J. Synthesis and biological evaluation of 3-(Substituted-benzylidene)-1,3-dihydro-indolin derivatives as human protein kinase ck2 and p60c-src tyrosine kinase inhibitors. Biol. Pharm. Bull., 2007, 30(4), 715-718.
104. Olgen, S.; Akaho, E.; Nebioglu, D. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies. IL. Farmaco., 2005, 60, 497-506.
105. Wood, E.R.; Kuyper, L.; Petrov, K.G.; Hunter, R.N.; Harris, P.A.; Lackey, K. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg. Med. Chem. Lett., 2004, 14, 953-957.
106. Lawrence, H.R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.S.; Szymanski, A.M.; Yip, M.L.R.; Guida, W.C.; Sebti, S.M.; Wu, J.; Lawrence, N.J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) based on oxindole scaffolds. J. Med. Chem., 2008, 51, 4948-4956.
107. Chen, L.; Pernazza, D.; Scott, L.M.; Lawrence, H.R.; Ren, Y.; Luo, Y.; Wub, X.; Sung, S.S.; Guida, W.C.; Sebti, S.M.; Lawrence, N.J.; Wu, J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem. Pharmacol., 2010, 80, 801-810.
108. Kastan, M.B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature., 2004, 432, 316-323.
109. Zhou, B.B.; Elledge, S.J. The DNA damage response: putting checkpoints in perspective. Nature., 2000, 408, 433-439.
110. Tao, ZF.; Lin, N.H. Chk1 inhibitors for novel cancer treatment. Anticancer. Agents. Med. Chem., 2006, 6, 377-378.
111. Hong, P.C.; Chen, L.J.; Lai, T.Y.; Yang, H.Y.; Chiang, S.J.; Lu, Y.Y.; Tsai, P.K.; Hsu, H.Y.; Wei, W.Y.; Liao, C.B. Synthesis of selenophene derivatives as novel CHK1 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 5065-5068.
112. Lin, N.H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Synthesis and biological evaluation of 3-ethylidene-1.;3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 421-426.
113. Hottecke, N.; Liebeck, M.; Baumann, K.; Schubenel, R.; Winkler, E.; Steiner, H.; Schmidt, B. Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ. Bioorg. Med. Chem. Lett., 2010, 20, 2958-2963.
114. Roth, G.J.; Heckel, A.; Brandl, T.; Grauert, M.; Hoerer, S.; Kley, J.T.; Schnapp, G.; Baum, P.; Mennerich, D.; Schnapp, A.; Park, J.E. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). J. Med. Chem., 2010, 53, 7287-7295.
115. Chen, C.H.; Lee, O.; Yao, C.N.; Chuang, M.Y.; Chang, Y.L.; Chang, M.H.; Wen, Y.F.; Yang, W.H.; Ko, C.H.; Chou, N.T.; Lin, M.W.; Lai, C.P.; Sun, C.Y.; Wang, L.M.; Chen, Y.C.; Hseu, T.H.; Chang, C.N.; Hsu, H.C.; Lin, H.C.; Chang, Y.L.; Shih, Y.C.; Chou, S.H.; Hsu, Y.L.; Tseng, H.W.; Liu, C.P.; Tu, C.M.; Hua, T.L.; Tsai, Y.J.; Chen, T.S.; Lin, C.L.; Chiou, S.J.; Liu, C.C.; Hwang, C.S. Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6129-6132.